Bristol-Myers Squibb Co., of New York, disclosed multiple regulatory milestones for its PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), including FDA acceptance for priority review of a biologics license application for previously treated advanced melanoma patients, with a PDUFA date of March 30, 2015.